Terry Benner

Terry Benner currently serves as the Director of Drug Substance Development at Checkpoint Therapeutics Inc., a position held since March 2022. Prior to this role, Terry had an extensive career at The Janssen Pharmaceutical Companies of Johnson & Johnson from March 2007 to March 2022, progressing through various titles including Associate Director of CMC Regulatory Affairs, Senior Scientist in API Large Molecule Development, and Scientist focusing on late-phase downstream processes. Earlier experience includes a role as Research Scientist I at AppTec Laboratory Services and a Process Technologist position at Centocor Inc. Terry holds a Master of Science in Quality Assurance/Regulatory Affairs from Temple University and a Bachelor of Science in Biology and Environmental Studies from Ursinus College.